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Abstract
The emergence of a novel A(H1N1) strain in 2009 was the first influenza pandemic of the genomic age, and unprecedented
surveillance of the virus provides the opportunity to better understand the evolution of influenza. We examined changes in
the nucleotide coding regions and the amino acid sequences of the hemagglutinin (HA), neuraminidase (NA), and
nucleoprotein (NP) segments of the A(H1N1)pdm09 strain using publicly available data. We calculated the nucleotide and
amino acid hamming distance from the vaccine strain A/California/07/2009 for each sequence. We also estimated Pepitope–a
measure of antigenic diversity based on changes in the epitope regions–for each isolate. Finally, we compared our results to
A(H3N2) strains collected over the same period. Our analysis found that the mean hamming distance for the HA protein of
the A(H1N1)pdm09 strain increased from 3.6 (standard deviation [SD]: 1.3) in 2009 to 11.7 (SD: 1.0) in 2013, while the mean
hamming distance in the coding region increased from 7.4 (SD: 2.2) in 2009 to 28.3 (SD: 2.1) in 2013. These trends are
broadly similar to the rate of mutation in H3N2 over the same time period. However, in contrast to H3N2 strains, the rate of
mutation accumulation has slowed in recent years. Our results are notable because, over the course of the study, mutation
rates in H3N2 similar to that seen with A(H1N1)pdm09 led to the emergence of two antigenic drift variants. However, while
there has been an H1N1 epidemic in North America this season, evidence to date indicates the vaccine is still effective,
suggesting the epidemic is not due to the emergence of an antigenic drift variant. Our results suggest that more research is
needed to understand how viral mutations are related to vaccine effectiveness so that future vaccine choices and
development can be more predictive.
Citation: Klein EY, Serohijos AWR, Choi J-M, Shakhnovich EI, Pekosz A (2014) Influenza A H1N1 Pandemic Strain Evolution – Divergence and the Potential for
Antigenic Drift Variants. PLoS ONE 9(4): e93632. doi:10.1371/journal.pone.0093632
Editor: Ce´cile Viboud, National Institutes of Health, United States of America
Received January 7, 2014; Accepted March 4, 2014; Published April 3, 2014
Copyright:  2014 Klein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by the Defense Advanced Research Projects Agency through grant HR0011-11-C-0093 and by the Models of Infectious Disease
Agent Study (MIDAS), under Award Number U01GM070708 from the National Institutes of General Medical Sciences, as well as a National Institutes of Health
Pioneer Award (DP1OD003874). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Office of Naval
Research or the official policy or position of the Department of Defense or the U.S. government. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: AP is an associate editor at PLOS Pathogens. This does not alter adherence to all PLOS policies on sharing data and materials. All other
authors have declared that no competing interests exist.
* E-mail: eklein@jhu.edu
Introduction
In April 2009, a novel human influenza A(H1N1) virus was
identified. This virus rapidly spread around the globe causing
significant morbidity and mortality in 2009/2010. This virus was
of swine origin [1,2] and contained a novel combination of gene
segments not previously reported in a human influenza virus
isolate [3]. Except for the elderly, the vast majority of individuals
around the world did not have protective immunity against the
virus and were thus susceptible to infection [4]. This relatively low
immunological pressure has presumably contributed to the fact
that there has been only limited antigenic change in the virus.
The primary target of the immune response to influenza is
generally the hemagglutinin (HA), a glycoprotein found on the
surface of the virus. Mutations in the HA protein enable the virus
to escape the neutralizing antibody response induced by vaccina-
tion or infection. Changes in the major antigenic epitopes are
believed to be primarily responsible for immune escape [5],
though changes outside these regions may also influence HA
antigenic structure and antibody binding strength. More generally,
evidence from equine and human challenge studies [6] suggest
that reinfection probability increases as the number of amino acid
differences between the primary infection/vaccine strain and the
challenge strain increase. Studies at the household level found
reinfection with human A(H3N2) occurred when the number of
amino acid mutations was between 9 and 22 [7]. In vitro studies of
the A(H1N1)pdm09 strain have shown that only one or two amino
acid changes can reduce the ability of human sera to bind viruses
of this strain [8].
Between April 2009 and April 2010, the Centers for Disease
Control and Prevention (CDC) estimate that there were ,61
million clinical cases of influenza in the US [9], and a further ,80
million people were vaccinated against the virus [10]. Prior
infection or vaccination precludes infection with a similar strain of
influenza because the HA proteins displayed on the surface of the
virus are targeted by existing antibodies. Immunity exerts pressure
on the virus to evolve rapidly, a process of antigenic change well
described in prior influenza epidemics. However, despite the
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potential for antigenic changes in the virus that may presage the
emergence of an antigenic drift variant, no quantification of the
magnitude of changes in the HA gene of the A(H1N1)pdm09
strain has been done on a global level. While geographically
limited assessments have shown changes in the sequence of the HA
gene [11–14], a global perspective is necessary because new strains
can spread around the globe in months or even weeks. In this
report we explore the evolution of the A(H1N1)pdm09 strain since
April 2009 at both the RNA and protein levels, altogether
constituting .9,000 sequences of A(H1N1)pdm09.
Methods
Both the nucleotide and amino acid sequences of the coding
regions and the sequences of the hemagglutinin (HA), neuramin-
idase (NA), and nucleoprotein (NP) segment coding regions were
obtained from the National Centre for Biotechnology Information
(NCBI) influenza virus resource [15]. Full-length sequences were
selected for all A/H1N1 samples collected from humans from 1/
1/2009 through 12/31/2013. Multiple sequence alignment was
calculated using MAFFT [16,17] with the FFT-NS-2 progressive
alignment algorithm. The multiple sequence alignment was
viewed with ClustalX [18].
Sequences were then compared base-pair by base-pair (nucle-
otides) and amino-acid by amino-acid (proteins) with the vaccine
strain (A/California/07/2009). While other options for measuring
pairwise distances are possible, we used the simplest metric, called
the Hamming distance. This metric assigns a zero or one
depending on whether two nucleotides or amino acids are
identical and has been widely used to cluster different influenza
strains [19]. We then defined the distance between two sequences
as the sum of the pairwise distances between their composite
nucleotides or amino acids. Divergence from the vaccine strain
was then calculated as the percentage of the sequence that was
identical to the vaccine strain.
Percentage divergence was used to identify the pandemic strains
using a relatedness criterion. After examining the way that the
different isolates clustered (see Figures S1, S2, S3, S4, S5 and S6),
strains with a similarity greater than a specific percentage were
considered pandemic strains and all subsequent analysis was on
these remaining strains. For HA and NA sequences, strains with a
relatedness greater than 90% to the vaccine strain were considered
A(H1N1)pdm09 strains, while for NP sequences we used 94% as
the cutoff. The pandemic strains were then sorted by collection
date. Strains with only the year of collection were excluded.
Strains that had year and month but not day were sorted at the
end of each month.
We then plotted the hamming distance of both the nucleotide
coding regions and the amino acids and calculated the rate of
mutation accumulation as the linear trend of the fit of the data.
Strains were also separated into two seasons per year, from April
to September and from October to March, and differences in the
mean hamming distance between seasons were tested for statistical
significance using a two-tailed student’s T-test. Linear trend
analysis and significance tests were done in R [20].
Epitope Analysis
Antibodies bind influenza virus primarily at the epitope regions
of the hemagglutinin protein [21]. Although other residues can
affect the geometry at the surface, and so can be under selective
pressure, they are not available for presentation to antibodies.
Thus, these epitopes are likely to be the predominant sites of
selection and increased change in those sites is suggestive of
immune escape. In addition, there have been suggestions of a
linear correlation between vaccine efficacy and the antigenic
distance of a strain at the epitopes from the vaccine strain [22].
Despite the importance of the epitope regions there is no
consensus on the epitope regions for A(H1N1)pdm09. We thus
examined three different possible models suggested in the
literature. The first was done by Deem et al. [5], which mapped
five epitope regions (A-E) from H3 onto a pandemic strain (A/
California/04/2009). The second one we used was proposed by
Huang et al. [23] and uses entropy and a likelihood ratio to define
a set of 41 natural epitopes that are a subset of the five epitope
regions defined by Deem et al. [5]. The third is the set of five
antigenic regions (Ca1, Ca2, Cb, Sa, Sb) defined from laboratory
studies on influenza virus A/PR/8/34 [24]. For each set of
epitope regions, we calculated the hamming distance for each
region as well as Pepitope, a measure of antigenic distance [25]
defined as,
Pepitope~
Number of amino acid differences
in the dominant epitope
Total number of amino acids
in the dominant epitope
ð1Þ
which can be used to estimate the likely efficacy of a vaccine
[22,25]. We also analyzed the rate of non-synonymous to
synonymous (dN/dS) changes in the coding region of the HA
gene across all the isolates using the vaccine strain as the basis for
comparison, focusing on the differences in the rates between
epitope (using the first definition) and non-epitope residues.
H3N2
We also conducted a similar analysis comparing changes in the
HA gene between A(H3N2) strains and the H3N2 vaccine strains.
Full-length H3N2 sequences were also downloaded from the
NCBI influenza virus resource [15] for the period 1/1/2009
through 12/31/2013. Multiple sequence alignment was again
calculated using MAFFT [16,17] with the FFT-NS-2 progressive
alignment algorithm, and the multiple sequence alignment was
viewed with ClustalX [18]. Finally, base-pair by base-pair
(nucleotides) and amino-acid by amino-acid (proteins) comparison
was done with the vaccine strain for each season as noted by the
WHO (http://www.who.int/influenza/vaccines/virus/
recommendations/en/). Thus, strains collected prior to April
2010, were compared to the A/Brisbane/10/2007 strain. Strains
collected between April 2010 and October 2012 were compared to
A/Perth/16/2009, and strains collected after October 2012 were
compared to vaccine strain A/Victoria/361/2011.
Results
We calculated the hamming distance for both the coding region
and the protein of the HA, NA, and NP gene segments for all
available fully sequenced strains of A(H1N1)pdm09 in the NCBI
influenza virus resource from April 1999 to December 2013. The
total number of HA sequences was 9,076 (includes one that was
dated March 30, 2009 but not the vaccine strain), though sampling
was not equal across the years, with the vast majority (75%)
sequenced between April 2009 and March 2010 (Table 1). There
were fewer fully sequenced NA and NP isolates, only 7,232 and
4,406, respectively. Despite these limitations, clear trends were
observed in the rate that the HA, NA, and NP genes and proteins
accumulated mutations.
Between April 2009 and December 2013, the coding region of
the hemagglutinin segment of the influenza H1N1 pandemic
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strain accumulated nucleotide mutations at a faster rate than the
coding regions of the NA and NP segments (Figure 1). We
estimated that the HA gene has been accumulating mutations at a
rate of approximately 5.68 (Standard Error [SE]: 0.03) mutations
per annum, or a rate of 3.361023 nucleotide substitutions per site
per year. This contrasts with the coding regions for the
neuraminidase and nucleoprotein segments which have been
accumulating mutations at a rate of only 3.56 (SE: 0.04) and 3.81
(SE: 0.05) mutations per annum, respectively, which is 2.561023
nucleotide substitutions per site per year for both.
The average hamming distance from the vaccine strain in the
RNA coding region for the HA gene increased from 7.4 (standard
deviation [SD]: 2.2) for strains collected in the initial season
between April 2009 and September 2009 to 24.8 (SD: 7.3) for the
2011–2012 northern hemisphere influenza season (Table 1). Each
year’s increase was statistically significant (p,0.01) both compared
to the prior season as well as the initial season. However, while the
following seasons were statistically different from the initial season
(p,0.01), the mean hamming distance has not significantly
changed since March 2012. This is also reflected in the mutation
accumulation rate, which was 6.54 (SE: 0.04) per annum, or a rate
of 3.861023 nucleotide substitutions per site per year, for the HA
gene between April 2009 and March 2012.
The hemagglutinin protein of the influenza H1N1 pandemic
strain has also been accumulating mutations at a faster rate than
the NA and NP proteins (Figure 2). We estimated that the HA
protein has been accumulating mutations at a rate of approxi-
mately 2.45 (SE: 0.02) mutations per annum, or 4.361023 amino
acid substitutions per site per year, while the neuraminidase and
nucleoprotein proteins have been accumulating mutations at a rate
of only 1.52 (SE: 0.02) and 0.26 (SE: 0.01) mutations per annum,
or a rate of 3.261023 and 0.5161023 amino acid substitutions
per-site per-year, respectively. Average hamming distance for the
HA protein from the vaccine strain increased from a mean of 3.6
(SD: 1.4) for strains collected between April 2009 and September
2009 to 11.7 (SD: 2.4) for strains collected between October 2011
and March 2012 (Table 1). Each year’s increase was also
statistically significant (p,0.01) both compared to the prior season
as well as the initial season. However, while again the 2012–2013
seasons were statistically different from the 2009–2010 season (p,
0.01), the mean hamming distance of the HA protein from the
vaccine has not significantly changed since March 2012.
While the last two seasons have not seen significant changes in
the mean hamming distance, this belies differences in the pattern
of mutations between seasons. For instance, the mutation D97N
fluctuates in frequency, though never reaching 50%, through
several seasons before becoming dominant in 10/2012–3/2013
season. On the other hand mutations S69T, S143G, A197T,
N260D, and V520A all became the consensus mutation in the
10/2011–3/2012 influenza season, appearing in ,70–80% of
sequences, but by the next year they all became much less
common and the dominant amino acid found is the wild type
(Table 2). A number of other mutations – P83S, S203T, and
I321V – were found in most sequences by the winter of 2009 and
have not waned in frequency. While, some mutations, S185T,
E374K, and S451N, continually increase in frequency each
season, other mutations (K163Q, K283E, A256T, and E499K) all
became the dominant sequence in 10/2013–3/2013 or later for
the first time after persisting at a low frequency for a number of
seasons. All the mutations described here were originally seen in at
least one sequence in 2009–2010, though this is not surprising as
nearly 70% of the amino acids have at least one mutation in one
isolate in the 10/2009–3/2010 season.
Epitopes
Because of the uncertainty regarding the location of the epitope
regions of the hemagglutinin protein, we examined mutations
using three different definitions for these regions: (1) a set of
epitopes defined by matching the epitopes to H3N2 [5]; (2) a
subset of the first set that are natural epitopes [23]; and (3) a set of
laboratory confirmed sites for prior seasonal H1N1 strains [24]. In
the first set, which encompasses the largest number of residues,
Figure 1. RNA Divergence of Influenza H1N1 Pandemic Strain, 2009–2013. Since April 2009, the coding region of the hemagglutinin
segment of the influenza H1N1 pandemic strain has been accumulating nucleotide mutations at a rate of approximately 5.68 mutations per annum
(A). This contrasts with the coding regions for the neuraminidase and nucleoprotein segments which have been accumulating mutations at a rate of
only 3.56 and 3.81 mutations per annum, respectively (B).
doi:10.1371/journal.pone.0093632.g001
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there are persistent mutational changes in epitopes B-E (Figure
S7), which results in an average of between 4 and 6 mutations in
the epitope regions by the 2011–2012 influenza season (Figure 3).
However as the mutations are spread around the epitopes, the
average Pepitope (which measures the proportion of changes in the
dominant epitope) is only 0.06 and 0.05 for the 10/2012–3/2013
and the 4/2013–9/2013 seasons, respectively, though the max
Pepitope during this period is 0.27. Using only the subset of those
residues which have been defined as natural epitopes we observed
fewer mutations in these residues, with the majority appearing in
epitope D (Figure S8). However, with a lower denominator,
average Pepitope calculated for these residues is 0.08 and 0.14 for
the 10/2012–3/2013 and the 4/2013–9/2013 seasons, respec-
tively, and a maximum value of 0.3. Lastly, for the laboratory
confirmed epitopes we observed that there were approximately 3
mutations in these residues on average in recent seasons, primarily
in the Ca1, Sa, and Sb regions (Figure S9). This resulted in a
Pepitope average value of 0.11 in both the 10/2012–3/2013 and the
4/2013–9/2013 seasons, and a maximum value of 0.42.
Analysis of the non-synonymous to synonymous mutations in
the epitope regions compared to the rest of the gene found that
dN/dS outside the epitope regions was fairly high in the first
couple seasons but has been approximately one in the last several
seasons. Conversely, within the epitope regions dN/dS has
generally been above unity (Figure S10).
H3N2
Annual influenza epidemics in the United States in the 2010–
2011, 2011–2012, and 2012–2013 seasons were predominated by
H3N2 influenza strains (http://www.cdc.gov/flu/weekly/
pastreports.htm). We calculated the hamming distance for both
the coding region and the protein of the HA gene segments for all
available fully sequenced isolates of A(H3N2) in the NCBI
influenza virus resource from January 1999 to December 2013.
The total number of HA sequences was 3,220, and sampling was
approximately equal across years. We then compared the number
of mutations that differed between collected strains in each season
with the recommended vaccine strain for that season, and
compared this to the evolution of A(H1N1)pdm09 over the period
of the study. This data indicates that H3N2 mutation rates similar
to that seen with A(H1N1)pdm09 led to the emergence of two
antigenic drift variants but no A(H1N1)pdm09 drift variants
emerged during the same timeframe (Figure 4).
Discussion
Since the emergence of the A(H1N1)pdm09 virus in 2009, only
a limited number of genetic or antigenic changes in the virus HA
gene/protein have been documented. Based on the detected
sequences, which remained antigenically homogeneous and closely
related to the vaccine virus, the recommended virus strain for
inclusion in the seasonal influenza vaccine remained an A/
California/07/2009-like virus for the 2013–2014 northern hemi-
sphere winter influenza season [26] as well as for the upcoming
2014 southern hemisphere influenza season [27] and the 2014–
2015 northern hemisphere winter influenza season. However, over
the past several seasons there have been a number of reports of
virus isolates containing amino acid changes in the HA protein
that have the potential to alter the antigenic properties of the virus
[8,28]. In this report we observe that the HA protein has
accumulated mutations both in total and within the epitope
regions that make the potential for vaccine escape highly probable.
This has important implications for evolutionary, epidemiological,
and clinical aspects of the virus.
From an evolutionary perspective, the HA gene has been
accumulating mutations more rapidly than the NA and NP genes,
however, the rate of nucleotide substitution and amino acid
substitution is lower than prior estimates [29]. While the faster
mutational drift of the HA gene is similar to past experience with
other H1N1 strains as well as with H3N2 strains, the slower rate of
Figure 2. Protein Divergence of Influenza H1N1 Pandemic Strain, 2009–2013. Since April 2009, the hemagglutinin protein of the influenza
H1N1 pandemic strain has been accumulating mutations at a rate of approximately 2.45 mutations per annum (A). This contrasts with the
neuraminidase and nucleoprotein proteins which have been accumulating mutations at a rate of only 1.52 and 0.26 mutations per annum,
respectively (B). In addition, there were more outliers present in 2013, which suggests that the population that was infected was smaller, presenting
opportunities for increasing diversity.
doi:10.1371/journal.pone.0093632.g002
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mutation is consistent with the theory that because most
individuals born after 1957 were susceptible to the virus, immune
pressure should have been relatively weaker, slowing the rate that
the virus evolved. Surprisingly though, we observed that the vast
majority of the mutations occurred during the 2009 to 2012 time
period, with only limited changes occurring over the last year. This
contrasts with H3N2 which has seen a continual increase in
mutational difference (Figure S11). This suggests that the two
viruses may be subject to different selective pressures on their
corresponding HA proteins.
Historically, for a new epidemic to occur, the HA protein of the
virus has to mutate enough to become antigenically distinct to a
significant percentage of individuals [30,31]. Prior studies suggest
that the probability that this will occur increases when the number
of amino acid substitutions in the HA protein exceeds 10 [6,7] or
the number of amino acid substitutions in the epitope regions
exceeds 4 [29]. This is also the pattern that we see with the
A(H3N2) data. Clinically the 2013–2014 season has so far been
marked by an influenza epidemic predominated by
A(H1N1)pdm09 [32]. This is consistent with the appearance of
prior epidemics given that the number of mutations in the HA
protein (particularly in the epitope regions) was similar in
magnitude to prior H1N1/H3N2 epidemics that were the result
of antigenic drift. However, while the estimated Pepitope scores
suggested that the vaccine may be only moderately effective
[22,33], the evidence to date indicates that the vaccine for the
2013–2014 season has been as effective as prior seasons [34,35].
The plateau in the hamming distance and the efficacy of the
vaccine suggests that an antigenic drift variant has not emerged
this season, despite an increase in the number of cases consistent
with an epidemic. These results could be explained by several
different reasons. The first is that potentially the vaccine does not
provide long-lasting immunity as a natural infection would and
individuals vaccinated in prior years are susceptible if they did not
get a vaccine this year. A second possibility is that because the
A(H1N1)pdm09 strain was a novel strain almost everyone was
susceptible, but many individuals may not have been infected
during the initial wave of infection leaving a large pool of
susceptible individuals that has been augmented with births of
naı¨ve children. Third, the mid-season results could just be due to
sampling bias and more sequences/studies may suggest an
alternative narrative. The first two cases suggest that improved
vaccination coverage would have contributed to fewer cases of
influenza this season.
We, as yet, cannot predict how influenza mutations will
accumulate or how these specific mutations will contribute to
influenza epidemics. For example, over the course of the study,
numerous genetic ‘outliers’ were sampled without a new epidemic
occurring. In fact there were three samples in which more than 40
amino acids differed from the vaccine strain identified prior to the
2012–2013 seasons. Why did these strains not start a new
epidemic? Excluding sequencing errors, one possibility is that they
could have been less transmissible relative to the dominant strain
and thus could not seed a new epidemic. Alternatively, as an
epidemic increases and there are more infected individuals, the
probability of genetic outliers appearing increases. However, as
they are outliers, the probability that they are transmitted is less
precisely because they are outliers (regardless of fitness – though
mutations generally reduce fitness, further reducing the likelihood
an outlier is selected). However, as the epidemic wanes the
likelihood of a genetic outlier appearing is less, but if one is
generated, the probability that it will spread is increased. This
suggests that variability (i.e. genetic diversity) in sampling is likely
to increase as the number of susceptible individuals wanes and the
seed of a new epidemic is likely to occur from these ‘outliers’.
Better predictions of how outliers are related to future epidemics
could lead to an increase in the efficiency of selecting future
vaccine strains.
Figure 3. Divergence at the A(H1N1)pdm09 epitopes. Changes
in the major antigenic epitopes are believed to be primarily responsible
for immune escape. We examined the total number of mutations in
these regions combined. However, there is disagreement as to the
amino acid locations encoding the epitope regions, thus we used three
potential descriptions of the epitope regions of the influenza
A(H1N1)pdm09 HA protein. The first (A) was based on the A(H3N2)
strain’s epitopes, the second (B) was a set of natural epitopes that is a
subset of the first set of epitopes, while the third (C) is a set of
laboratory confirmed epitopes for prior H1N1 strains. All three show
divergence (i.e. an increase in the number of hamming distance) in the
epitope regions, particularly the first and third definitions.
doi:10.1371/journal.pone.0093632.g003
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Despite the important epidemiological and clinical implications
of this work, it is not without limitations. First of all, estimates of
antigenic drift and vaccine effectiveness are based in large part on
changes in the epitope regions of the HA protein, however, there is
no consensus on the exact location of these epitopes. In addition,
the most recent H3N2 epidemic was due in large part to changes
in the structure of the epitopes that occurred outside the clearly
defined epitope region. Second, the samples we used were not
randomly selected, but were drawn from available sequences.
These sequences are largely from individuals that were hospital-
ized in western countries and so likely represent only a fraction of
the potential diversity. Regions outside of the west may play a
large role in the evolution of influenza. For instance, while the
most significant outliers from 2013 were from Kenya, African
isolates account for only a small fraction of the total number in the
database. Better geographic surveillance would increase the
potential for identifying antigenic drift in the virus and improve
the capacity to make vaccine strain choices. Despite these
limitations, the extremely large number of samples heralds a
new era in genomic surveillance and promises to increase our
knowledge and understanding as to how influenza evolves. It also
suggests a need for tools to be developed that allow quick and easy
interpretation of newly sequenced isolates within the context of
other sequences so that decisions on surveillance and interventions
can be optimally provided. Crucially it also suggests more research
is needed to understand how viral mutations are related to vaccine
effectiveness so that future vaccine choices can be more predictive.
Conclusion
The vast number of A(H1N1)pdm09 sequences provides a
means of understanding the evolution of influenza and potentially
predicting new epidemics. Data of this sort can be used to develop
theories and predictions as to how future viruses may evolve and
provide data for vaccine optimization. Ideally, computational and
in vitro methods could be used to generate vaccine strains that
would be predictive rather than reactive, but a better understand-
ing of influenza intra-host diversity and transmission is required to
start developing such techniques. While the future evolutionary
paths of the A(H1N1)pdm09 strain are not fully known and subject
to as yet undetermined ecological and environmental effects due to
interactions with other strains and pathogens, the number of
mutations in the HA protein suggest that there is a high
probability of an antigenic drift variant in the A(H1N1)pdm09
strain occurring in the near future, and surveillance should be
geared to look for such changes.
Supporting Information
Figure S1 Influenza A(H1N1)pdm09 Strain Selection,
Hemagglutinin RNA. All H1N1 RNA coding sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of nucleotides that
were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S2 Influenza A(H1N1)pdm09 Strain Selection,
Hemagglutinin Protein. All H1N1 protein sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of amino acids
Figure 4. Comparison of A(H1N1)pdm09 and A(H3N2) evolution in the Hemagglutinin gene. We measured the hamming distance of the
nucleotides (A) and the amino acids (B) relative to the vaccine strain for the particular season. For H1N1 the vaccine strain (A/California/07/2009) has
not changed since 2009, though it was not administered until November 2009. For H3N2 the vaccine strain was changed twice over the study (where
the vertical lines are). Thus, strains collected prior to April 2010, were compared to the A/Brisbane/10/2007 strain. Strains collected between April
2010 and October 2012 were compared to A/Perth/16/2009, and strains collected after October 2012 were compared to vaccine strain A/Victoria/361/
2011.
doi:10.1371/journal.pone.0093632.g004
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that were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S3 Influenza A(H1N1)pdm09 Strain Selection,
Neuraminidase RNA. All H1N1 RNA coding sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of nucleotides that
were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S4 Influenza A(H1N1)pdm09 Strain Selection,
Neuraminidase Protein. All H1N1 protein sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of amino acids
that were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S5 Influenza A(H1N1)pdm09 Strain Selection,
Nucleoprotein RNA. All H1N1 RNA coding sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of nucleotides that
were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S6 Influenza A(H1N1)pdm09 Strain Selection,
Nucleoprotein Protein. All H1N1 protein sequences from
January 1, 2009 to September 30, 2013 were compared to the
H1N1 pandemic vaccine strain (A/California/07/2009) and
scored for divergence based on the percentage of amino acids
that were similar at each position. The resulting clusters were then
separated and non-pandemic strains – those with a divergence
greater than the dashed grey line – were excluded from further
analysis.
(GIF)
Figure S7 Divergence at the A(H1N1)pdm09 epitopes,
definition 1. We used three potential descriptions of the epitope
regions of the influenza A(H1N1)pdm09 HA protein. The present
one was based on the A(H3N2) strain’s epitopes. A-E refers to the
different epitopes, while F is the Pepitope calculation measuring the
proportion of amino acid differences in the dominant epitope, for
each strain.
(GIF)
Figure S8 Divergence at the A(H1N1)pdm09 epitopes,
definition 2. We used three potential descriptions of the epitope
regions of the influenza A(H1N1)pdm09 HA protein. The present
one is a set of natural epitopes that is a subset of the first set of
epitopes. A-E refers to the different epitopes, while F is the Pepitope
calculation measuring the proportion of amino acid differences in
the dominant epitope, for each strain.
(GIF)
Figure S9 Divergence at the A(H1N1)pdm09 epitopes,
definition 3. We used three potential descriptions of the epitope
regions of the influenza A(H1N1)pdm09 HA protein. The present
one is a set of laboratory confirmed epitopes for prior H1N1
strains. A-E refers to the different epitopes, Ca1, Ca2, Cb, Sa, Sb,
while F is the Pepitope calculation measuring the proportion of amino
acid differences in the dominant epitope, for each strain.
(GIF)
Figure S10 Non-Synonymous and Synonymous Muta-
tions in A(H1N1)pdm09. We calculated the ratio of non-
synonymous to synonymous mutations (dN/dS) for
A(H1N1)pdm09 strains relative to the vaccine strain (A/Califor-
nia/07/2009) for regions outside the epitope regions (A) and
within the epitope regions (B) using the first definition of the
epitope regions (see methods). The straight line denotes unity,
which is generally considered the neutral mutation rate.
(GIF)
Figure S11 Comparison of A(H1N1)pdm09 and A(H3N2)
evolution in the Hemagglutinin gene. We measured the
hamming distance of the nucleotides (A) and the amino acids (B)
relative to the vaccine strain for 2009. For H1N1 the vaccine strain
(A/California/07/2009) has not changed since 2009, though it
was not administered until November 2009. For H3N2 all isolates
were compared to the A/Brisbane/10/2007 strain, though the
vaccine has changed twice since then. While the hamming
distance of H3N2 isolates from the vaccine strain continues to
increase, the H1N1 isolates seem to have plateaued in recent
years.
(GIF)
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